StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$515.02−5.64 (-1.08%)

Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –

Vertex Pharmaceuticals TRIKAFTA / KAFTRIO by Quarter

TRIKAFTA / KAFTRIO (elexacaftor/tezacaftor/ivacaftor) — Net product revenues ($M) ($M)

Vertex Pharmaceuticals TRIKAFTA / KAFTRIO: $2,497M in Q2 2026, down 2.1% from a year earlier.

Latest, Q2 2026
2,497
Period ended Jun 30, 2026
Change on a year earlier
-2.1%
2,551 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Revenue Disaggregation Note & Form 8-K.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTRIKAFTA / KAFTRIO (elexacaftor/tezacaftor/ivacaftor) — Net product revenues ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20262,497-2.1%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 31, 20262,355-7.1%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 20252,573-5.5%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 20252,654+2.7%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 20252,551+4.2%Form 10-Q (filed 2026-08-04) ↗
Q1 2025Mar 31, 20252,536+2.1%Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 20242,721+16.6%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 20242,585+13.7%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 20242,449+9.3%Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 20242,484+18.5%Form 10-Q (filed 2025-05-06) ↗
Q4 2023Dec 31, 20232,333+15.4%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 20232,274+13.1%Form 10-Q (filed 2024-11-05) ↗
Q2 2023Jun 30, 20232,240+18.3%Form 10-Q (filed 2024-08-02) ↗
Q1 2023Mar 31, 20232,097+19.0%Form 10-Q (filed 2024-05-07) ↗
Q4 2022Dec 31, 20222,022+19.4%Form 10-K (filed 2025-02-13) ↗
Q3 2022Sep 30, 20222,011+29.2%Form 10-Q (filed 2023-11-07) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals TRIKAFTA / KAFTRIO ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rev-trikafta-kaftrio

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?